Addressing Immune Resistance and Reason to Believe
Cancer scientists have recognized an emerging hallmark of cancer referred to as immune evasion, or as immune resistance—the ability for cancer cells to evade the immune system.
Although considerable progress has been made in understanding how cancers induce immune evasion, thus causing resistance to treatment interventions, including immunotherapy, additional research is still needed. Following immunotherapeutic interventions, indeed only 30% of cancer patients respond optimally, thus demonstrating the urgency to explore the underlying reasons leading to such phenomena more in depth.
At the Saint John’s Cancer Institute, the Rosalie and Harold Rae Brown Cancer Immunotherapy Research Program is addressing this problem by enabling high throughput immune fingerprints (molecular functional profiles), at baseline and following therapeutic interventions, to facilitate precision medicine and help select: (i) patients who benefit most to treatment interventions, (ii) treatments that are most appropriate and effective for patients.